Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
615.2 INR | +0.19% | +18.29% | +21.94% |
May. 14 | GRIFOLS SHARES DOWN 4.8% AFTER GOTHAM CITY RESEARCH ISSUES REPOR… | RE |
May. 13 | Aarti Pharmalabs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Sales 2022 | 12K 999K | Sales 2023 | 19.45K 1.62M | Capitalization | 25B 2,081B |
---|---|---|---|---|---|
Net income 2022 | 1.22B 102B | Net income 2023 | 1.94B 161B | EV / Sales 2022 * | - |
Net Debt 2022 | 2.58B 215B | Net Debt 2023 | 1.52B 127B | EV / Sales 2023 | 1,363,395 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
12.9
x | Employees | 2,042 |
Yield 2022 * |
-
| Yield 2023 |
0.73% | Free-Float | 52.07% |
1 day | +0.19% | ||
1 week | +18.29% | ||
Current month | +19.89% | ||
1 month | +23.33% | ||
3 months | +15.32% | ||
6 months | +51.85% | ||
Current year | +21.94% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 22-10-16 | |
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 22-10-16 |
Piyush Lakhani
DFI | Director of Finance/CFO | - | 22-10-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hetal Gogri Gala
CEO | Chief Executive Officer | 48 | 22-10-16 |
Chairman | 49 | 21-08-06 | |
Director/Board Member | 77 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 614 | +1.05% | 473,046 |
24-05-16 | 607.6 | +3.51% | 1,334,391 |
24-05-15 | 587 | -5.02% | 1,384,675 |
24-05-14 | 618 | +18.84% | 7,438,200 |
24-05-13 | 520 | +3.50% | 476,891 |
Delayed Quote NSE India S.E., May 18, 2024 at 03:02 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+21.94% | 668M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- AARTIPHARM Stock